Kovid Trivedi, MD
Pulmonary Disease · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · Sutter Delta Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Trivedi’s office to ask if they take your plan before you enroll.
State licence records
1 licence
- Illinois 125060240Temporary Medical Permit · since 2011 · expires 2014-07-06Specialty on the licence: Internal MedicineExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Sutter Delta Medical CenterAntioch, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.173, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Sutter Delta Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 5 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.173 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.98 (0 to 2.03) · 561 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.47 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 176.46 (114.75 to 238.17) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 113 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.3 · 260 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 1,274 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.02 to 0.46) · 3,285 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,374 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.47 (1.02 to 5.93) · 364 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.16 (0.49 to 3.83) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.63 (0 to 18.4) · 26 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 81 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.24 (0 to 1.07) · 2,713 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.962 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 116 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 316 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 20 · 83 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.1 · 298 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.3 · 269 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 283 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.7 to 17.1) · 529 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 45 cases | No different | Jan 2024 – Dec 2024 |
What patients said (610 patients answered, 13% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 70% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 60% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 64% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$91,096
Medicare paid this office $91,096 for 240 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 123 | $40,937 | $160 |
| Long return visit (40+ min) | 65 | $11,178 | $116 |
| Critical care, each additional 30 minutes | 45 | $7,723 | $80 |
| Return visit (30+ min) | 41 | $4,031 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,707 | $90 |
See all 12 services
| Critical care, first 30-74 minutes | 123 | $40,937 | $160 |
| Long return visit (40+ min) | 65 | $11,178 | $116 |
| Critical care, each additional 30 minutes | 45 | $7,723 | $80 |
| Return visit (30+ min) | 41 | $4,031 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,707 | $90 |
| New patient visit (60+ min) | 12 | $1,672 | $139 |
| Test to examine how well the lungs exchange gases | 31 | $1,284 | $40 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 29 | $855 | $29 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 49 | $828 | $13 |
| Test to determine lung volumes using sensors | 14 | $646 | $43 |
| Test to determine lung volumes using gas dilution or washout | 14 | $426 | $30 |
| Ultrasonic guidance for blood vessel access | 12 | $135 | $10 |
Who their Medicare patients are
240 Original Medicare patients in 2024. Average age 72 · Under 65 21% · 85 and older 10% · Women 48% · Also on Medicaid 36% · Health risk score 2.78. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · COPD 52% · Coronary heart disease 48% · Heart failure 48% · Diabetes 45% · Atrial fibrillation 42% · Chronic kidney disease 37% · Depression 32% · Cancer 19% · Stroke 18% · Dementia 15%.
The office billed $269,820, Medicare allowed $118,579 and paid $91,096; for 1,281 services of 45 kinds; $14,417 of it was for drugs given in the office and $76,679 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 240 | 1,281 | 72 | 2.78 | $269,820 | $91,096 |
| 2023 | 274 | 4,499 | 72 | 2.02 | $512,185 | $193,512 |
| 2022 | 269 | 2,570 | 72 | 2.06 | $405,754 | $148,262 |
| 2021 | 263 | 4,361 | 72 | 2.43 | $515,376 | $197,415 |
| 2020 | 289 | 3,129 | 72 | 2.43 | $449,463 | $173,230 |
| 2019 | 300 | 1,140 | 72 | 2.31 | $319,035 | $105,586 |
| 2018 | 374 | 1,290 | 71 | 2.58 | $366,476 | $117,120 |
| 2017 | 143 | 361 | 72 | 2.00 | $97,430 | $31,397 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Critical care, first 30-74 minutes | 107 | $37,170 | $160 |
| Long return visit (40+ min) | 104 | $22,056 | $124 |
| Critical care, each additional 30 minutes | 55 | $11,404 | $81 |
| Return visit (30+ min) | 61 | $6,174 | $76 |
| New patient visit (60+ min) | 41 | $5,994 | $146 |
| Test to examine how well the lungs exchange gases | 52 | $2,384 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,358 | $91 |
| Test to determine lung volumes using gas dilution or washout | 52 | $1,864 | $33 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 13 | $1,581 | $105 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 46 | $1,446 | $29 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 17 | $624 | $35 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 26 | $509 | $14 |
| Administration of influenza virus vaccine | 11 | $325 | $30 |
| Test to measure oxygen level in blood using ear or finger device continuously overnight | 11 | $213 | $18 |
| Evaluation of use of breathing device | 17 | $211 | $12 |
2022: 15 services
| Critical care, first 30-74 minutes | 95 | $32,703 | $165 |
| Long return visit (40+ min) | 74 | $15,162 | $135 |
| Critical care, each additional 30 minutes | 60 | $12,987 | $83 |
| Return visit (30+ min) | 60 | $7,060 | $86 |
| New patient visit (60+ min) | 39 | $6,327 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $3,356 | $78 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,713 | $151 |
| Test to examine how well the lungs exchange gases | 39 | $1,835 | $43 |
| Test to determine lung volumes using gas dilution or washout | 38 | $1,353 | $32 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 34 | $1,162 | $30 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 11 | $769 | $70 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 18 | $367 | $15 |
| Administration of influenza virus vaccine | 12 | $339 | $28 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 11 | $224 | $20 |
| Evaluation of use of breathing device | 16 | $218 | $13 |
2021: 14 services
| Critical care, first 30-74 minutes | 110 | $38,700 | $171 |
| Critical care, each additional 30 minutes | 71 | $17,532 | $86 |
| Long return visit (40+ min) | 47 | $9,675 | $136 |
| Return visit (30+ min) | 73 | $9,297 | $88 |
| New patient visit (60+ min) | 29 | $4,578 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $3,074 | $81 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 11 | $1,221 | $111 |
| Test to examine how well the lungs exchange gases | 22 | $1,039 | $43 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $931 | $52 |
| Test to determine lung volumes using gas dilution or washout | 22 | $760 | $33 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 13 | $400 | $29 |
| Test to measure expiratory airflow and volume | 11 | $254 | $23 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 11 | $183 | $15 |
| Evaluation of use of breathing device | 11 | $144 | $13 |
2020: 15 services
| Critical care, first 30-74 minutes | 130 | $48,370 | $174 |
| Critical care, each additional 30 minutes | 93 | $21,209 | $88 |
| Long return visit (40+ min) | 43 | $6,559 | $104 |
| Return visit (30+ min) | 64 | $6,421 | $76 |
| Telephone medical discussion with physician, 21-30 minutes | 58 | $5,867 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $3,451 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,553 | $160 |
| New patient visit (60+ min) | 16 | $2,343 | $146 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 24 | $1,159 | $43 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 13 | $1,013 | $68 |
| Test to examine how well the lungs exchange gases | 17 | $917 | $42 |
| Test to determine lung volumes using gas dilution or washout | 14 | $509 | $32 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 16 | $372 | $15 |
| Ultrasonic guidance for blood vessel access | 14 | $240 | $11 |
| Administration of influenza virus vaccine | 11 | $198 | $16 |
2019: 17 services
| Critical care, first 30-74 minutes | 126 | $39,677 | $173 |
| Critical care, each additional 30 minutes | 76 | $19,254 | $87 |
| Long return visit (40+ min) | 63 | $10,127 | $99 |
| Return visit (30+ min) | 73 | $8,194 | $77 |
| New patient visit (60+ min) | 49 | $7,277 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $3,358 | $80 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 60 | $2,926 | $45 |
| Test to examine how well the lungs exchange gases | 41 | $1,915 | $42 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 11 | $1,346 | $112 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 16 | $1,216 | $68 |
| Test to determine lung volumes using gas dilution or washout | 33 | $1,071 | $32 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 18 | $362 | $14 |
| Evaluation of use of breathing device | 25 | $318 | $12 |
| Test to measure oxygen level in blood using ear or finger device continuously overnight | 12 | $271 | $19 |
| Ultrasonic guidance for blood vessel access | 15 | $216 | $11 |
| Administration of influenza virus vaccine | 13 | $210 | $16 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 11 | $205 | $19 |
2018: 21 services
| Critical care, first 30-74 minutes | 163 | $47,302 | $174 |
| Critical care, each additional 30 minutes | 80 | $17,280 | $87 |
| Return visit (30+ min) | 87 | $9,673 | $73 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $7,756 | $82 |
| Long return visit (40+ min) | 54 | $7,068 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,124 | $159 |
| New patient visit (60+ min) | 26 | $4,044 | $156 |
| New patient visit (45+ min) | 19 | $2,201 | $116 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 49 | $2,166 | $44 |
| Test to examine how well the lungs exchange gases | 41 | $1,725 | $41 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 11 | $1,007 | $77 |
| Test to determine lung volumes using gas dilution or washout | 30 | $993 | $33 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 11 | $614 | $51 |
| Evaluation of use of breathing device | 44 | $584 | $12 |
| Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | 18 | $401 | $22 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 20 | $382 | $14 |
| Administration of influenza virus vaccine | 18 | $339 | $19 |
| Test to measure expiratory airflow and volume | 11 | $307 | $28 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 23 | $242 | $10 |
| Test to measure oxygen level in blood using ear or finger device continuously overnight | 11 | $229 | $19 |
| Ultrasonic guidance for blood vessel access | 13 | $193 | $11 |
2017: 10 services
| Critical care, first 30-74 minutes | 29 | $7,470 | $174 |
| Return visit (30+ min) | 55 | $5,159 | $78 |
| New patient visit (60+ min) | 18 | $2,876 | $160 |
| New patient visit (45+ min) | 22 | $2,704 | $123 |
| Critical care, each additional 30 minutes | 15 | $2,613 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $2,438 | $81 |
| Long return visit (40+ min) | 20 | $2,183 | $109 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 13 | $657 | $47 |
| Test to examine how well the lungs exchange gases | 12 | $545 | $39 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 13 | $211 | $14 |
Medicaid work
$77,471 in 2024
Medicaid paid $77,471 for 578 billed services this clinician did in 2024, up to 38 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 447 | $66,541 |
| Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service) | 59 | $5,976 |
| Long return visit (40+ min) | 50 | $4,833 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 22 | $121 |
| 2024 | 578 | 4 | 38 | $77,471 |
| 2023 | 620 | 7 | 25 | $66,400 |
| 2022 | 366 | 4 | 25 | $49,693 |
| 2021 | 582 | 3 | 19 | $64,216 |
| 2020 | 839 | 5 | 31 | $83,214 |
| 2019 | 838 | 4 | 23 | $96,991 |
| 2018 | 684 | 6 | 26 | $65,208 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 429 | $52,452 |
| Long return visit (40+ min) | 117 | $10,122 |
| Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service) | 15 | $1,562 |
| Return visit (30+ min) | 15 | $637 |
| Diffusing capacity | 15 | $599 |
| EVALUATION OF WHEEZING | 14 | $563 |
| Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes | 15 | $464 |
2022
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 229 | $36,362 |
| Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service) | 60 | $7,644 |
| Long return visit (40+ min) | 48 | $4,137 |
| Return visit (30+ min) | 29 | $1,551 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 392 | $47,962 |
| Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service) | 145 | $13,627 |
| Return visit (30+ min) | 45 | $2,627 |
2020
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 468 | $52,505 |
| Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service) | 265 | $24,390 |
| Return visit (30+ min) | 62 | $4,269 |
| Long return visit (40+ min) | 14 | $1,298 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 30 | $753 |
2019
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 414 | $59,643 |
| Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service) | 267 | $25,950 |
| Return visit (30+ min) | 119 | $8,125 |
| Long return visit (40+ min) | 38 | $3,274 |
2018
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 348 | $40,928 |
| Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service) | 123 | $12,223 |
| Return visit (30+ min) | 129 | $8,575 |
| Long return visit (40+ min) | 31 | $2,877 |
| Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes | 37 | $581 |
| EVALUATION OF WHEEZING | 16 | $26 |
Drugs they prescribed that Part D paid
$1,325,536
Pharmacies billed $1,325,536 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,776) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
594 generic and 1,182 brand-name prescriptions · $1,325,536 in drug cost · 20 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 437 | $350,734 | $803 |
| Ofev | 19 | $248,832 | $13,096 |
| Aralast NP | 11 | $121,194 | $11,018 |
| Tezspire | 24 | $110,548 | $4,606 |
| Breztri Aerosphere | 137 | $95,398 | $696 |
See all 25 drugs
| Trelegy Ellipta | 437 | $350,734 | $803 |
| Ofev | 19 | $248,832 | $13,096 |
| Aralast NP | 11 | $121,194 | $11,018 |
| Tezspire | 24 | $110,548 | $4,606 |
| Breztri Aerosphere | 137 | $95,398 | $696 |
| Dupixent | 15 | $57,078 | $3,805 |
| Breo Ellipta | 72 | $39,372 | $547 |
| Spiriva Respimat | 53 | $35,492 | $670 |
| Anoro Ellipta | 56 | $30,622 | $547 |
| Stiolto Respimat | 49 | $29,828 | $609 |
| Symbicort | 55 | $18,513 | $337 |
| Budesonide-Formoterol | 35 | $10,764 | $308 |
| Fluticasone-Salmeterol | 47 | $7,367 | $157 |
| Albuterol Sulfate Hfa | 213 | $5,814 | $27 |
| Roflumilast | 80 | $5,670 | $71 |
| Fluticasone Propionate Hfa | 22 | $3,984 | $181 |
| Breyna | 15 | $2,896 | $193 |
| Ventolin Hfa | 30 | $1,970 | $66 |
| Budesonide | 12 | $1,754 | $146 |
| Montelukast | 138 | $1,253 | $9 |
| Omeprazole | 17 | $409 | $24 |
| Azelastine | 13 | $224 | $17 |
| Azithromycin | 12 | $202 | $17 |
| Prednisone | 50 | $181 | $4 |
| Fluticasone Propionate | 12 | $123 | $10 |
Year by year
| 2024 | 1,776 | 215 | 0% (0) | 67% | $1,325,536 |
| 2023 | 1,915 | 259 | 0% (0) | 70% | $1,543,900 |
| 2022 | 1,679 | 217 | 0% (0) | 74% | $1,192,672 |
| 2021 | 1,631 | 196 | 0% (0) | 80% | $1,029,787 |
| 2020 | 1,604 | 191 | 0% (0) | 79% | $789,397 |
| 2019 | 1,638 | 218 | 0% (0) | 78% | $635,325 |
| 2018 | 1,472 | 204 | 0% (0) | 71% | $402,402 |
| 2017 | 340 | 101 | 0% (0) | 63% | $67,828 |
| 2016 | 117 | 16 | None | 44% | $15,365 |
| 2015 | 126 | 20 | None | 79% | $153,480 |
| 2014 | 17 | None | 0% (0) | None | $16,215 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Trelegy Ellipta | 500 | $395,884 | $792 |
| Ofev | 23 | $270,320 | $11,753 |
| Aralast NP | 11 | $132,012 | $12,001 |
| Breztri Aerosphere | 135 | $93,703 | $694 |
| Pirfenidone | 11 | $91,427 | $8,312 |
| Breo Ellipta | 99 | $49,235 | $497 |
| Nucala | 14 | $49,036 | $3,503 |
| Stiolto Respimat | 70 | $47,287 | $676 |
| Dupixent | 13 | $45,884 | $3,530 |
| Symbicort | 72 | $42,137 | $585 |
| Anoro Ellipta | 65 | $32,987 | $507 |
| Spiriva Respimat | 44 | $26,543 | $603 |
| Roflumilast | 80 | $12,270 | $153 |
| Advair Diskus | 19 | $12,202 | $642 |
| Combivent Respimat | 11 | $11,541 | $1,049 |
| Flovent Hfa | 22 | $8,222 | $374 |
| Varenicline | 18 | $8,163 | $453 |
| Albuterol Sulfate Hfa | 234 | $7,209 | $31 |
| Advair Hfa | 11 | $6,069 | $552 |
| Arnuity Ellipta | 15 | $5,606 | $374 |
| Ventolin Hfa | 47 | $2,948 | $63 |
| Montelukast | 148 | $1,866 | $13 |
| Fluticasone-Salmeterol | 11 | $1,173 | $107 |
| Prednisone | 82 | $483 | $6 |
| Omeprazole | 13 | $381 | $29 |
| Azelastine | 12 | $326 | $27 |
| Azithromycin | 14 | $257 | $18 |
| Fluticasone Propionate | 15 | $211 | $14 |
| Doxycycline Hyclate | 14 | $210 | $15 |
2022: 22 drugs
| Trelegy Ellipta | 463 | $361,931 | $782 |
| Letairis | 12 | $145,930 | $12,161 |
| Aralast NP | 11 | $133,668 | $12,152 |
| Breo Ellipta | 128 | $57,951 | $453 |
| Nucala | 15 | $48,783 | $3,252 |
| Breztri Aerosphere | 67 | $44,240 | $660 |
| Stiolto Respimat | 81 | $43,464 | $537 |
| Symbicort | 80 | $38,100 | $476 |
| Dupixent | 11 | $37,653 | $3,423 |
| Anoro Ellipta | 69 | $35,827 | $519 |
| Daliresp | 46 | $26,451 | $575 |
| Spiriva Respimat | 48 | $25,374 | $529 |
| Combivent Respimat | 14 | $8,721 | $623 |
| Albuterol Sulfate Hfa | 174 | $7,406 | $43 |
| Flovent Hfa | 15 | $5,652 | $377 |
| Ventolin Hfa | 47 | $2,985 | $64 |
| Tadalafil | 12 | $2,238 | $186 |
| Montelukast | 125 | $2,041 | $16 |
| Prednisone | 72 | $454 | $6 |
| Omeprazole | 16 | $374 | $23 |
| Azithromycin | 12 | $338 | $28 |
| Fluticasone Propionate | 12 | $239 | $20 |
2021: 23 drugs
| Trelegy Ellipta | 348 | $265,828 | $764 |
| Esbriet | 13 | $123,445 | $9,496 |
| Zemaira | 16 | $81,179 | $5,074 |
| Anoro Ellipta | 122 | $64,942 | $532 |
| Symbicort | 106 | $55,339 | $522 |
| Breo Ellipta | 115 | $52,580 | $457 |
| Stiolto Respimat | 83 | $45,337 | $546 |
| Daliresp | 90 | $43,652 | $485 |
| Dupixent | 13 | $41,478 | $3,191 |
| Spiriva Respimat | 52 | $26,719 | $514 |
| Combivent Respimat | 26 | $16,441 | $632 |
| Spiriva | 18 | $10,286 | $571 |
| Breztri Aerosphere | 13 | $7,782 | $599 |
| Albuterol Sulfate Hfa | 162 | $7,180 | $44 |
| Arnuity Ellipta | 22 | $5,432 | $247 |
| Wixela Inhub | 19 | $4,617 | $243 |
| Budesonide-Formoterol | 11 | $4,272 | $388 |
| Ventolin Hfa | 63 | $3,641 | $58 |
| Montelukast | 101 | $1,922 | $19 |
| Azithromycin | 20 | $1,116 | $56 |
| Prednisone | 46 | $383 | $8 |
| Omeprazole | 14 | $238 | $17 |
| Bupropion Hcl Sr | 14 | $180 | $13 |
2020: 27 drugs
| Trelegy Ellipta | 247 | $182,216 | $738 |
| Zemaira | 12 | $109,247 | $9,104 |
| Anoro Ellipta | 178 | $96,186 | $540 |
| Breo Ellipta | 105 | $47,082 | $448 |
| Spiriva Respimat | 85 | $44,162 | $520 |
| Stiolto Respimat | 66 | $38,229 | $579 |
| Symbicort | 65 | $36,257 | $558 |
| Daliresp | 62 | $28,301 | $456 |
| Spiriva | 33 | $18,581 | $563 |
| Combivent Respimat | 28 | $15,166 | $542 |
| Arnuity Ellipta | 40 | $9,892 | $247 |
| Wixela Inhub | 33 | $7,907 | $240 |
| Albuterol Sulfate Hfa | 144 | $6,820 | $47 |
| Chantix | 14 | $6,435 | $460 |
| Advair Hfa | 11 | $6,263 | $569 |
| Flovent Hfa | 15 | $5,290 | $353 |
| Dulera | 15 | $4,749 | $317 |
| Budesonide-Formoterol | 14 | $3,949 | $282 |
| Proair Hfa | 53 | $3,844 | $73 |
| Fluticasone-Salmeterol | 11 | $2,662 | $242 |
| Ventolin Hfa | 39 | $2,282 | $59 |
| Montelukast | 100 | $1,637 | $16 |
| Azithromycin | 28 | $1,130 | $40 |
| Xopenex Hfa | 13 | $924 | $71 |
| Proair Respiclick | 13 | $819 | $63 |
| Prednisone | 65 | $356 | $5 |
| Bupropion Hcl Sr | 18 | $255 | $14 |
2019: 25 drugs
| Anoro Ellipta | 216 | $99,535 | $461 |
| Trelegy Ellipta | 146 | $99,009 | $678 |
| Stiolto Respimat | 106 | $53,373 | $504 |
| Spiriva Respimat | 94 | $48,805 | $519 |
| Breo Ellipta | 102 | $39,446 | $387 |
| Symbicort | 79 | $36,516 | $462 |
| Spiriva | 52 | $30,336 | $583 |
| Daliresp | 52 | $22,268 | $428 |
| Combivent Respimat | 35 | $14,698 | $420 |
| Advair Diskus | 28 | $12,963 | $463 |
| Proair Hfa | 110 | $10,445 | $95 |
| Advair Hfa | 12 | $6,527 | $544 |
| Chantix | 11 | $4,732 | $430 |
| Incruse Ellipta | 12 | $4,147 | $346 |
| Arnuity Ellipta | 16 | $3,802 | $238 |
| Albuterol Sulfate Hfa | 76 | $3,593 | $47 |
| Ventolin Hfa | 50 | $3,124 | $62 |
| Fluticasone-Salmeterol | 15 | $3,005 | $200 |
| Montelukast | 148 | $2,189 | $15 |
| Azithromycin | 39 | $1,098 | $28 |
| Doxycycline Hyclate | 11 | $549 | $50 |
| Prednisone | 65 | $409 | $6 |
| Bupropion Xl | 11 | $358 | $33 |
| Fluticasone Propionate | 13 | $287 | $22 |
| Omeprazole | 17 | $185 | $11 |
2018: 25 drugs
| Spiriva Respimat | 134 | $60,995 | $455 |
| Anoro Ellipta | 128 | $54,027 | $422 |
| Stiolto Respimat | 122 | $49,998 | $410 |
| Symbicort | 113 | $43,819 | $388 |
| Breo Ellipta | 73 | $26,808 | $367 |
| Advair Diskus | 57 | $26,468 | $464 |
| Trelegy Ellipta | 34 | $20,648 | $607 |
| Combivent Respimat | 41 | $17,251 | $421 |
| Daliresp | 39 | $15,818 | $406 |
| Spiriva | 33 | $15,697 | $476 |
| Flovent Hfa | 22 | $8,712 | $396 |
| Dulera | 25 | $8,360 | $334 |
| Advair Hfa | 14 | $7,234 | $517 |
| Proair Hfa | 89 | $6,595 | $74 |
| Bevespi Aerosphere | 14 | $5,768 | $412 |
| Ventolin Hfa | 61 | $3,438 | $56 |
| Budesonide | 11 | $2,878 | $262 |
| Asmanex | 12 | $2,389 | $199 |
| Azithromycin | 51 | $1,864 | $37 |
| Montelukast | 143 | $1,765 | $12 |
| Prednisone | 91 | $882 | $10 |
| Omeprazole | 40 | $366 | $9 |
| Fluticasone Propionate | 17 | $204 | $12 |
| Doxycycline Hyclate | 11 | $196 | $18 |
| Sulfamethoxazole-Trimethoprim | 13 | $89 | $7 |
2017: 13 drugs
| Spiriva Respimat | 32 | $13,714 | $429 |
| Symbicort | 29 | $9,279 | $320 |
| Stiolto Respimat | 24 | $8,138 | $339 |
| Combivent Respimat | 15 | $5,175 | $345 |
| Advair Diskus | 12 | $4,955 | $413 |
| Spiriva | 12 | $4,430 | $369 |
| Breo Ellipta | 11 | $4,180 | $380 |
| Proair Hfa | 19 | $1,189 | $63 |
| Azithromycin | 19 | $512 | $27 |
| Prednisone | 33 | $288 | $9 |
| Omeprazole | 20 | $154 | $8 |
| Montelukast | 13 | $147 | $11 |
| Fluticasone Propionate | 11 | $111 | $10 |
2016: 3 drugs
| Clarithromycin | 12 | $1,293 | $108 |
| Ethambutol | 16 | $919 | $57 |
| Prednisone | 14 | $60 | $4 |
2015: 3 drugs
| Spiriva | 20 | $7,030 | $351 |
| Daliresp | 15 | $3,971 | $265 |
| Symbicort | 13 | $3,658 | $281 |
Money from drug and device companies
$35,353 in 2025
| 2025 | 12 | 100 | $26,347 | $35,353 |
| 2024 | 15 | 69 | $20,210 | $24,727 |
| 2023 | 16 | 68 | $2,800 | $9,362 |
| 2022 | 20 | 52 | None | $2,374 |
| 2021 | 12 | 51 | None | $678 |
| 2020 | 13 | 39 | None | $1,084 |
| 2019 | 20 | 90 | None | $1,288 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Breztri | $28,463 | 54 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $3,833 | 9 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $1,795 | 13 payments
|
| Genzyme | Dupixent | $366 | 6 payments
|
| Regeneron Healthcare Solutions | Dupixent | $256 | 6 payments
|
| United Therapeutics | Orenitram | $166 | 4 payments
|
See all 100 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-19 | Fasenra | $25 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-17 | Ofev | $137 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-12-16 | Breztri | $1,074 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-15 | None | $41 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-15 | None | $60 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-15 | None | $41 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-15 | None | $50 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-15 | None | $137 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-12-15 | None | $226 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-12-05 | Breztri | $2,148 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-03 | None | $60 |
| GlaxoSmithKline | Meals · 2025-11-13 | Nucala | $22 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-11-13 | Breztri | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-13 | Breztri | $113 |
| Pulmonx | Meals · 2025-11-12 | Chartis Catheter | $39 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-11-12 | Breztri | $300 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-30 | Tezspire | $34 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-10-27 | Fasenra | $2,150 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-10-27 | None | $563 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-10-23 | Fasenra | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-23 | Fasenra | $110 |
| Regeneron Healthcare Solutions | Meals · 2025-10-20 | Dupixent | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-19 | Airsupra | $48 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-19 | None | $120 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-19 | None | $119 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-14 | None | $82 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-10-09 | Fasenra | $1,600 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-10-09 | Fasenra | $125 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-08 | Fasenra | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-08 | Tezspire | $33 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-10-07 | Fasenra | $28 |
| Intuitive Surgical | Meals · 2025-10-07 | Da Vinci Surgical System | $94 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-02 | Breztri | $22 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-10-02 | Fasenra | $125 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-02 | None | $96 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-09-26 | Fasenra | $1,600 |
| GlaxoSmithKline | Meals · 2025-09-25 | Trelegy Ellipta | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-23 | Fasenra | $35 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-09-23 | Fasenra | $27 |
| Regeneron Healthcare Solutions | Education · 2025-09-19 | Dupixent | $3 |
| Regeneron Healthcare Solutions | Meals · 2025-09-19 | Dupixent | $46 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-17 | Fasenra | $33 |
| Genzyme | Meals · 2025-09-11 | Dupixent | $36 |
| Intuitive Surgical | Meals · 2025-09-06 | Da Vinci Surgical System | $662 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-09-04 | Fasenra | $3,200 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-09-02 | Fasenra | $250 |
| Verona Pharma | Meals · 2025-08-28 | Ohtuvayre | $115 |
| United Therapeutics | Meals · 2025-08-27 | Tyvaso | $26 |
| United Therapeutics | Meals · 2025-08-21 | None | $64 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-08-20 | Fasenra | $800 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-19 | Fasenra | $108 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-08-19 | Fasenra | $69 |
| Genzyme | Meals · 2025-08-06 | Dupixent | $115 |
| United Therapeutics | Meals · 2025-07-30 | Orenitram | $33 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-07-25 | Airsupra | $1,050 |
| Genzyme | Meals · 2025-07-25 | Dupixent | $27 |
| Intuitive Surgical | Travel · 2025-07-25 | Da Vinci Surgical System | $37 |
| Intuitive Surgical | Travel · 2025-07-25 | Da Vinci Surgical System | $246 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-07-16 | Fasenra | $125 |
| GlaxoSmithKline | Meals · 2025-07-15 | Nucala | $115 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-07-15 | Airsupra | $1,050 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-14 | None | $53 |
| United Therapeutics | Meals · 2025-07-11 | None | $43 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-10 | Breztri | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-10 | Fasenra | $35 |
| Intuitive Surgical | Meals · 2025-07-08 | Da Vinci Surgical System | $15 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-07-03 | Fasenra | $250 |
| Genzyme | Meals · 2025-06-18 | Dupixent | $6 |
| Sanofi-Aventis U.S. | Education · 2025-05-30 | Dupixent | $98 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-28 | None | $37 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-05-21 | Airsupra | $450 |
| Genzyme | Meals · 2025-05-21 | Dupixent | $74 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-19 | Fasenra | $117 |
| Regeneron Pharmaceuticals | Meals · 2025-05-18 | Dupixent | $31 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-18 | None | $147 |
| Regeneron Healthcare Solutions | Meals · 2025-05-17 | Dupixent | $85 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-16 | None | $134 |
| Genzyme | Meals · 2025-05-08 | Dupixent | $108 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-05-07 | Airsupra | $1,050 |
| Regeneron Healthcare Solutions | Meals · 2025-04-24 | Dupixent | $37 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-04-23 | Breztri | $1,050 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-16 | None | $124 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-04-11 | Breztri | $2,150 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-04-09 | Breztri | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-09 | Breztri | $135 |
| Itamar Medical | Meals · 2025-04-04 | Watchpatone | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-26 | None | $118 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-19 | Ofev | $121 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-17 | None | $5 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-03-10 | Breztri | $4,300 |
| Intuitive Surgical | Education · 2025-03-10 | Da Vinci Surgical System | $2,500 |
| Intuitive Surgical | Meals · 2025-03-10 | Da Vinci Surgical System | $16 |
| Regeneron Healthcare Solutions | Meals · 2025-03-07 | Dupixent | $58 |
| Intuitive Surgical | Travel · 2025-03-05 | Da Vinci Surgical System | $258 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-03-04 | Breztri | $161 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-04 | Breztri | $123 |
| Intuitive Surgical | Travel · 2025-03-03 | Da Vinci Surgical System | $6 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-02-26 | Breztri | $1,050 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-21 | None | $35 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-02-18 | Airsupra | $450 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $24,727
| AstraZeneca Pharmaceuticals LP | Breztri | $17,121 | 32 payments
|
| Genzyme | Dupixent | $6,767 | 10 payments
|
| Regeneron Healthcare Solutions | Dupixent | $267 | 6 payments
|
| GlaxoSmithKline | Nucala | $191 | 4 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $92 | 1 payment
|
| United Therapeutics | Remodulin | $61 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $42 | 2 payments
|
| Merck Sharp & Dohme | Zerbaxa | $38 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Adempas | $33 | 2 payments
|
| Phathom Pharmaceuticals | Voquezna | $31 | 1 payment
|
| Novartis Pharmaceuticals | Xolair | $22 | 1 payment
|
| Avadel CNS Pharmaceuticals | Lumryz | $17 | 1 payment
|
| Harmony Biosciences | Wakix | $16 | 1 payment
|
| Philips North America | (Ak6) Vest Therapy | $16 | 1 payment
|
| Sandoz | Treprostinil | $14 | 1 payment
|
2023: $9,362
| AstraZeneca Pharmaceuticals LP | Airsupra | $4,905 | 19 payments
|
| Noah Medical | None | $2,087 | 4 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $1,716 | 6 payments
|
| GlaxoSmithKline | Nucala | $143 | 8 payments
|
| United Therapeutics | Tyvaso | $86 | 4 payments
|
| Philips Electronics North America | (8874) Incourage | $63 | 4 payments
|
| Avadel CNS Pharmaceuticals | Lumryz | $60 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $57 | 3 payments
|
| Grifols USA | Prolastin-C Liquid | $48 | 3 payments
|
| Baxter Healthcare | Hillrom - Vest System Model 105 Home Care | $45 | 2 payments
|
| Genentech USA | Xolair | $34 | 2 payments
|
| Insmed | Arikayce | $32 | 2 payments
|
| Axsome Therapeutics | Sunosi | $29 | 1 payment
|
| Jazz Pharmaceuticals | Xywav | $23 | 1 payment
|
| Foundation Medicine | None | $16 | 1 payment
|
| Pfizer | Paxlovid | $16 | 1 payment
|
2022: $2,374
| Intuitive Surgical | Da Vinci Surgical System | $992 | 7 payments
|
| Ethicon | Monarch Platform | $658 | 4 payments
|
| United Therapeutics | Tyvaso | $139 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $88 | 5 payments
|
| GlaxoSmithKline | Nucala | $70 | 5 payments
|
| Amgen | Tezspire | $58 | 3 payments
|
| Actelion Pharmaceuticals US | Opsumit | $53 | 2 payments
|
| Gilead Sciences | None | $39 | 3 payments
|
| Merck Sharp & Dohme | Zerbaxa | $33 | 2 payments
|
| Genzyme | Cablivi | $31 | 2 payments
|
| Grifols USA | Prolastin-C Liquid | $30 | 2 payments
|
| Novartis Pharmaceuticals | Xolair | $28 | 2 payments
|
| Insmed | Arikayce | $25 | 2 payments
|
| Jazz Pharmaceuticals | Xywav | $25 | 1 payment
|
| Covis Pharma GmBH | Tudorza Pressair | $21 | 1 payment
|
| Genentech USA | Xolair | $19 | 1 payment
|
| Baxter Healthcare | Hillrom - Life 2000 Ventilation System | $18 | 1 payment
|
| La Jolla Pharmaceutical | Giapreza | $17 | 1 payment
|
| Harmony Biosciences | Wakix | $14 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $13 | 1 payment
|
2021: $678
| GlaxoSmithKline | Nucala | $171 | 17 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $158 | 10 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $111 | 6 payments
|
| United Therapeutics | Tyvaso | $64 | 3 payments
|
| Grifols USA | Prolastin-C Liquid | $50 | 3 payments
|
| Actelion Pharmaceuticals US | Opsumit | $23 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $23 | 1 payment
|
| La Jolla Pharmaceutical | Giapreza | $22 | 1 payment
|
| Insmed | Arikayce | $16 | 1 payment
|
| Gilead Sciences | None | $15 | 1 payment
|
| Genentech USA | Xolair | $13 | 1 payment
|
| Amgen | None | $11 | 1 payment
|
2020: $1,084
| Covidien LP | Superdimension | $608 | 6 payments
|
| GlaxoSmithKline | Nucala | $195 | 14 payments
|
| Genentech USA | Xolair | $85 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Symbicort | $56 | 4 payments
|
| Actelion Pharmaceuticals US | Uptravi | $28 | 2 payments
|
| Genzyme | Dupixent | $24 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $18 | 1 payment
|
| Novartis Pharmaceuticals | Xolair | $16 | 1 payment
|
| Insmed | Arikayce | $13 | 1 payment
|
| EUSA Pharma (US) | Sylvant | $13 | 1 payment
|
| Mylan Specialty L.P. | Yupelri | $13 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $11 | 1 payment
|
| Veran Medical Technologies | Spin | $4 | 1 payment
|
2019: $1,288
| GlaxoSmithKline | Nucala | $339 | 29 payments
|
| AstraZeneca Pharmaceuticals LP | Symbicort | $193 | 12 payments
|
| Actelion Pharmaceuticals US | Uptravi | $102 | 7 payments
|
| Sunovion Pharmaceuticals | Lonhala Magnair | $99 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Spiriva Respimat | $93 | 4 payments
|
| Genentech USA | Xolair | $73 | 4 payments
|
| Genzyme | Dupixent | $48 | 2 payments
|
| Insmed | Arikayce | $47 | 3 payments
|
| Mylan Specialty L.P. | Yupelri | $44 | 3 payments
|
| Grifols USA | Prolastin-C Liquid | $42 | 3 payments
|
| Novartis Pharmaceuticals | Xolair | $41 | 3 payments
|
| Shire North American Group | Glassia | $41 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Adempas | $32 | 2 payments
|
| Gilead Sciences | None | $21 | 1 payment
|
| Merck Sharp & Dohme | Zerbaxa | $15 | 1 payment
|
| Circassia Pharmaceuticals | Tudorza Pressair | $15 | 1 payment
|
| Mallinckrodt Enterprises | Acthar | $13 | 1 payment
|
| Teva Pharmaceuticals USA | Cinqair | $12 | 1 payment
|
| Pfizer | Chantix | $11 | 1 payment
|
| Veran Medical Technologies | Spin | $8 | 1 payment
|
Professional record
- NPI
- 1033406566
- Licence
- IL 125060240Illinois 125060240: Expired
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X)
- Mailing address
- Po Box 276950, Sacramento, CA, 95827
- NPI first listed
- 2011-07-05
- NPI last updated
- 2025-03-11
- NPI record certified
- 2025-03-11
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3333 Green Bay Rd, North Chicago, IL, 60064